Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 11/2019

01-10-2019 | Thyroidectomy | Endocrine Tumors

Distinct Clinical Manifestations of Thyroid Cancer After Hematopoietic Stem Cell Transplantation

Authors: Tae Yoon Lee, MD, Sohee Lee, MD, PhD, Ja Seong Bae, MD, PhD, Woo-Chan Park, MD, PhD, Sung-Soo Park, MD, PhD, Sung-Eun Lee, MD, PhD, Jong Wook Lee, MD, PhD, Seong Koo Kim, MD, Bin Cho, MD, PhD, Chan Kwon Jung, MD, PhD

Published in: Annals of Surgical Oncology | Issue 11/2019

Login to get access

Abstract

Background

The incidence of a secondary solid malignancy after hematopoietic cell transplantation (HCT) is increasing in long-term survivors.

Objective

The aim of this study was to compare the clinicopathological characteristics of HCT recipients with secondary thyroid cancer (STC), with those of non-HCT thyroid cancer patients.

Methods

We retrospectively investigated 5184 patients who received HCT between 1983 and 2016. Of these, 18 patients developed STC and underwent thyroidectomy due to differentiated thyroid cancer. We compared the clinicopathological characteristics of post-HCT thyroid cancer patients (post-HCT group) with those of a primary differentiated thyroid carcinoma cohort (cohort group) from Seoul St. Mary’s Hospital.

Results

The mean ages at HCT and thyroidectomy after HCT were 22.0 and 31.8 years, respectively, and the median time interval between HCT and thyroidectomy was 5 years (range 1–16). Compared with the cohort group, the post-HCT group was younger at cancer onset and frequently had a palpable mass at initial diagnosis. The post-HCT group had more aggressive features, including larger tumor size, frequent extrathyroidal extension, lymphatic invasion, perineural invasion, and frequent lateral neck node metastasis and distant metastasis, relative to the cohort group; however, most patients (83.2%) in the post-HCT group were stage I or II. Additionally, BRAF V600E mutation was less frequent in the post-HCT group.

Conclusions

We found that STC after HCT showed younger presentation and more aggressive clinical presentation. Therefore, a policy of regular screening, including neck ultrasound examination, may promote early detection and treatment in HCT recipients.
Appendix
Available only for authorised users
Literature
1.
Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol. 2001;19(2):464–71.CrossRefPubMed
2.
Majhail NS, Tao L, Bredeson C, et al. Prevalence of hematopoietic cell transplant survivors in the United States. Biol Blood Marrow Transpl. 2013;19(10):1498–1501.CrossRef
3.
4.
Bresters D, Lawitschka A, Cugno C, et al. Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters. Bone Marrow Transplant. 2016;51(11):1482–89.CrossRefPubMed
5.
Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336(13):897–904.CrossRefPubMed
6.
Deeg HJ, Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood. 1998;91(6):1833–44.PubMedCrossRef
7.
Socié G, Curtis RE, Deeg HJ, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol. 2000;18(2):348–57.CrossRefPubMed
8.
Cohen A, Rovelli A, van Lint MT, et al. Secondary thyroid carcinoma after allogeneic bone marrow transplantation during childhood. Bone Marrow Transplant. 2001;28(12):1125–28.CrossRefPubMed
9.
Cohen A, Rovelli A, Merlo DF, et al. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study. J Clin Oncol. 2007;25(17):2449–54.CrossRefPubMed
10.
11.
Danner-Koptik KE, Majhail NS, Brazauskas R, et al. Second malignancies after autologous hematopoietic cell transplantation in children. Bone Marrow Transplant. 2013;48(3):363–8.CrossRefPubMed
12.
Inamoto Y, Shah NN, Savani BN, et al. Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant. 2015;50(8):1013–23.CrossRefPubMedPubMedCentral
13.
Nelson AS, Ashton LJ, Vajdic CM, et al. Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy. Leukemia. 2015;29(2):441–7.CrossRefPubMed
14.
Ehrhardt MJ, Brazauskas R, He W, Rizzo JD, Shaw BE. Survival of patients who develop solid tumors following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;51(1):83–8.CrossRefPubMed
15.
Cohen A, Bekassy AN, Gaiero A, et al. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplant. 2008;41 Suppl 2:S43–8.CrossRefPubMed
16.
Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. Arch Intern Med. 1996;156(19):2165–72.CrossRefPubMed
17.
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.
18.
Jung CK, Im SY, Kang YJ, et al. Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma. Thyroid. 2012;22(8):791–7.CrossRefPubMed
19.
American Joint Committee on Cancer. AJCC Cancer Staging Manual, 7th edn, Springer; 2010. pp. 87–7.
20.
Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic”—screening and overdiagnosis. N Engl J Med. 2014;371(19):1765–67.CrossRefPubMed
21.
Ahn HS, Kim HJ, Kim KH, et al. Thyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality. Thyroid. 2016;26(11):1535–40.CrossRefPubMed
22.
Ho WL, Zacharin MR. Thyroid carcinoma in children, adolescents and adults, both spontaneous and after childhood radiation exposure. Eur J Pediatr. 2016;175(5):677–83.CrossRefPubMed
23.
24.
Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res. 1995;141(3):259–77.CrossRefPubMed
25.
Francis GL, Waguespack SG, Bauer AJ, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015;25(7):716–59.CrossRefPubMedPubMedCentral
26.
Clement SC, Kremer LC, Links TP, et al. Is outcome of differentiated thyroid carcinoma influenced by tumor stage at diagnosis? Cancer Treat Rev. 2015;41(1):9–16.CrossRefPubMed
27.
Molenaar RJ, Sidana S, Radivoyevitch T, et al. Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer. J Clin Oncol. 2018;36(18):1831–9.CrossRefPubMed
28.
Silva-Vieira M, Carrilho Vaz S, Esteves S, et al. Second primary cancer in patients with differentiated thyroid cancer: Does radioiodine play a role? Thyroid. 2017;27(8):1068–76.CrossRefPubMed
Metadata
Title
Distinct Clinical Manifestations of Thyroid Cancer After Hematopoietic Stem Cell Transplantation
Authors
Tae Yoon Lee, MD
Sohee Lee, MD, PhD
Ja Seong Bae, MD, PhD
Woo-Chan Park, MD, PhD
Sung-Soo Park, MD, PhD
Sung-Eun Lee, MD, PhD
Jong Wook Lee, MD, PhD
Seong Koo Kim, MD
Bin Cho, MD, PhD
Chan Kwon Jung, MD, PhD
Publication date
01-10-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 11/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07442-4

Other articles of this Issue 11/2019

Annals of Surgical Oncology 11/2019 Go to the issue

Breast Oncology

Radiological Staging for Distant Metastases in Breast Cancer Patients with Confirmed Local and/or Locoregional Recurrence: How Useful are Current Guideline Recommendations?

Endocrine Tumors

Risk of Distant Metastasis in Parathyroid Carcinoma and Its Effect on Survival: A Retrospective Review from a High-Volume Center

ASO Author Reflections

ASO Author Reflections: The American Society of Breast Surgeons Definition of Oncoplastic Surgery

Gastrointestinal Oncology

Impact of ypT, ypN, and Adjuvant Therapy on Survival in Gastric Cancer Patients Treated with Perioperative Chemotherapy and Radical Surgery

Gastrointestinal Oncology

Obstruction-Free Survival Following Operative Intervention for Malignant Bowel Obstruction in Appendiceal Cancer

Breast Oncology

Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis